Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 2 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Anti-amyloid antibody Medicines | Treatment |
Mixed
whyA statistically detectable but very small cognitive effect (ADAS-Cog SMD -0.11) alongside 107 more cases of ARIA-E per 1,000. The reviewers' own conclusion is that removing amyloid does not seem to produce clinically meaningful effects — the sharpest disagreement in this table with how the individual trials were reported. |
ADAS-Cog and CDR-SB at 18 months; ARIA | meta-analysis | 20,342 | ADAS-Cog SMD -0.11 (95% CI -0.16 to -0.06); ARIA-E absolute risk difference +107 per 1,000 |
Cochrane Database of Systematic Reviews
2026 ✓ Peer-reviewed PMID 41985900 |
| Anti-amyloid antibody Medicines | Treatment |
Mixed
whyBenefits were statistically present but every one fell below the minimum clinically important difference, against a number needed to harm of 9 for ARIA-oedema. Agrees with the Cochrane review and not with the trial reports. |
Cognitive and functional scales against the MCID; ARIA | meta-analysis | 23,202 | CDR-SB mean difference -0.18 (95% CI -0.34 to -0.03), below the MCID; ARIA-oedema NNH 9 |
Annals of Family Medicine
2024 ✓ Peer-reviewed PMID 38253509 |